Shilpa Medicare has received U.S Food and Drug
Administration tentative approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg,
and 30 mg dated 04 Mar 2021. The ANDA was filed as 'First to File' submission on
NCE -1 date to seek eligibility for 180 days exclusivity.
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA.
According to IQVIA MAT Q2 2020 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
